Sellas' blood cancer immunotherapy cuts death risk in trial
Published 1 d ago1 sourceEvidence: Reported
The US approved a DNA-based immunotherapy for recurrent respiratory papillomatosis, marking a notable step in therapeutic options for this rare disease. The approval signals regulatory acceptance of a novel nucleic-acid platform, though broader clinical and market impact remains to be seen.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 3 h ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported